FDA alerts providers to recall of drug to treat serious bacterial infections
The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.
Related News Articles
Headline
There are now 602 cases in the Utah measles outbreak, the state’s Department of Health and Human Services reported April 14. Of those, 405 cases have been…
Headline
The Utah measles outbreak has increased to 583 cases, the state’s Department of Health and Human Services reported April 7. Of those, 386 cases have been…
Headline
Cases in the Utah measles outbreak have increased to 559, the state’s Department of Health and Human Services reported March 31. The agency said 362 cases have…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Blog
h2, h3, h4 {color: #002855;}
Postpartum hemorrhage (PPH) is one of the most common — and preventable — causes of maternal health in the United States. The…
Chairperson's File
For decades, hospitals and health systems have used innovation to improve patient care and outcomes. We have seen dramatic improvements and know we can never…